Tolerability and efficacy of antialdosterone therapy with canrenone in heart failure: Experience in the real world of a dedicated outpatient department;Tollerabilità ed efficacia dell'inibizione aldosteronica con canrenone nello scompenso cardiaco: L'esperienza nel mondo reale di un ambulatorio dedicato

Italian Heart Journal, Supplement

Volumn 6, Issue 1, 2005, Pages

  Nassiacos, Daniele ^a   Meloni, Sabina ^a  

^a Ospedale di Saronno   (Italy)

Author keywords

ACE inhibitors; Beta blockers; Canrenone; Heart failure; Hyperkalemia

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CANRENONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM;

ADULT; AGED; AMBULATORY CARE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; REVIEW; SUDDEN DEATH; TIME; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; AMBULATORY CARE; CANRENONE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 29244460053     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
2. Pitt B, Remme WJ, Zannad F, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.
4. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993; 71: 3C-11C.
5. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-65.
6. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-5.
7. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.
8. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.
9. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-20.
10. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141: 1901-4.
11. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-75.
12. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71: 3A-11A.
13. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effect of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259-65.
14. Ramires FJ, Mansur A, Coehlo O, Maranhao M, Mady C, Ramires JF Spironolactone and ventricular arrhythmias in patients with heart failure, (abstr) Circulation 1998; 98 (Suppl I): I-300.
15. Cittadini A, Monti MG, Isgaard J, et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 2003; 58: 555-64.
16. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51.
17. Gottlieb S. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients, (news) BMJ 2004; 329: 420.
18. Maggioni AP, Gorini M, a nome del Working Group on Heart Failure ANMCO. IN-CHF: Italian Network on outpatients with congestive heart failure. Firenze: Centro Studi ANMCO, 2004.
19. Goodman LS, Limbird LE, Milinoff PB, Ruddon RW, Goodman Gilman A. Goodman's & Gillman's the pharmacological basis of therapeutics. 9th edition. New York, NY: McGraw-Hill, 1997: 707-9.
20. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-7.
21. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002; 40: 304-10.
22. Remme WJ, Swedberg K, on behalf of the Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
23. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2001; 38: 2101-13.
24. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
25. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
26. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
27. Pfeffer MA, Brauwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
28. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-6.
29. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
30. The CIBIS Committee. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
31. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-65.
32. St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 2003; 107: 2577-82.
33. MacFayden RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-4.
34. Gorini M, a nome del Working Group on Heart Failure ANMCO. Fattori predittivi di mortalità ad 1 anno in 3327 pazienti ambulatoriali con scompenso cardiaco. Dati della Rete ANMCO "Software Scompenso Cardiaco". (abstr) G Ital Cardiol 1998; 28 (Suppl 2): 27.
35. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13: S107-S112.
36. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (Suppl A): 6A-13A.
37. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72 (Suppl): S3-S9.